Sign In
Buy PIII
P3 Health Partners Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$4.85 |
| EPS actual | $0.320 |
| EPS Surprise | 106.60% |
| Revenue estimate | 391.45M |
| Revenue actual | 386.39M |
| Revenue Surprise | -1.29% |
| Release date | Mar 26, 2026 |
| EPS estimate | -$8.06 |
| EPS actual | -$23.02 |
| EPS Surprise | -185.49% |
| Revenue estimate | 353.68M |
| Revenue actual | 384.814M |
| Revenue Surprise | 8.80% |
| Release date | Nov 14, 2025 |
| EPS estimate | -$5.29 |
| EPS actual | -$9.67 |
| EPS Surprise | -82.71% |
| Revenue estimate | 346.642M |
| Revenue actual | 345.253M |
| Revenue Surprise | -0.401% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$3.29 |
| EPS actual | -$6.23 |
| EPS Surprise | -89.36% |
| Revenue estimate | 344.909M |
| Revenue actual | 355.788M |
| Revenue Surprise | 3.15% |
Last 4 Quarters for P3 Health Partners
Below you can see how PIII performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $6.94 |
| EPS estimate | -$3.29 |
| EPS actual | -$6.23 |
| EPS surprise | -89.36% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $6.70 |
| Aug 11, 2025 | $6.60 |
| Aug 12, 2025 | $6.63 |
| Aug 13, 2025 | $7.10 |
| Aug 14, 2025 | $6.94 |
| Aug 15, 2025 | $6.78 |
| Aug 18, 2025 | $6.95 |
| Aug 19, 2025 | $7.17 |
| Aug 20, 2025 | $7.32 |
| 4 days before | 3.58% |
| 4 days after | 5.40% |
| On release day | -2.38% |
| Change in period | 9.18% |
| Release date | Nov 14, 2025 |
| Price on release | $6.84 |
| EPS estimate | -$5.29 |
| EPS actual | -$9.67 |
| EPS surprise | -82.71% |
| Date | Price |
|---|---|
| Nov 10, 2025 | $7.50 |
| Nov 11, 2025 | $7.51 |
| Nov 12, 2025 | $7.62 |
| Nov 13, 2025 | $7.00 |
| Nov 14, 2025 | $6.84 |
| Nov 17, 2025 | $5.98 |
| Nov 18, 2025 | $6.40 |
| Nov 19, 2025 | $6.12 |
| Nov 20, 2025 | $5.87 |
| 4 days before | -8.80% |
| 4 days after | -14.18% |
| On release day | -12.57% |
| Change in period | -21.73% |
| Release date | Mar 26, 2026 |
| Price on release | $2.79 |
| EPS estimate | -$8.06 |
| EPS actual | -$23.02 |
| EPS surprise | -185.49% |
| Date | Price |
|---|---|
| Mar 20, 2026 | $2.90 |
| Mar 23, 2026 | $3.03 |
| Mar 24, 2026 | $2.97 |
| Mar 25, 2026 | $3.11 |
| Mar 26, 2026 | $2.79 |
| Mar 27, 2026 | $2.94 |
| Mar 30, 2026 | $2.96 |
| Mar 31, 2026 | $3.08 |
| Apr 01, 2026 | $2.74 |
| 4 days before | -3.79% |
| 4 days after | -1.79% |
| On release day | 5.38% |
| Change in period | -5.52% |
| Release date | May 14, 2026 |
| Price on release | $4.03 |
| EPS estimate | -$4.85 |
| EPS actual | $0.320 |
| EPS surprise | 106.60% |
| Date | Price |
|---|---|
| May 08, 2026 | $3.55 |
| May 11, 2026 | $3.78 |
| May 12, 2026 | $3.77 |
| May 13, 2026 | $3.57 |
| May 14, 2026 | $4.03 |
| May 15, 2026 | $11.29 |
| May 18, 2026 | $9.17 |
| May 19, 2026 | $10.49 |
| May 20, 2026 | $9.69 |
| 4 days before | 13.59% |
| 4 days after | 140.45% |
| On release day | 180.15% |
| Change in period | 173.12% |
P3 Health Partners Earnings Call Transcript Summary of Q1 2026
P3 Health Partners reported a strong Q1 2026 driven by structural contract changes, improved clinical/operational execution, and a modestly improving macro environment. Key financials: $386M revenue, $26M adjusted EBITDA (versus a loss in Q1 2025), medical claims of $306M with $17M of favorable prior-year development/payer settlements, medical loss ratio ~85.2% (adjusted), and cash of $25M. At-risk membership was ~106k (down from 118k) after deliberate portfolio pruning; total lives under management ~135k. Medicare Advantage per-member funding improved ~15% year-over-year; Q1 MA medical cost trend was roughly flat to 2025 (and P3 had <2% MA trend in 2025). Management completed capital-structure actions (≈$250M debt converted to preferred equity plus up to $70M additional preferred issuance) intended to cure NASDAQ equity compliance and strengthen the balance sheet. Company raised its 2026 adjusted EBITDA guidance to $20M–$60M (midpoint $40M) while noting range variability from claims development and execution. Management emphasized continued focus on markets/payers with delegation, deeper Tier 1 provider concentration, utilization management, payment integrity, and selective investment in frontline clinical capabilities.
